Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Nankivell

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
British Journal of Cancer|March 25, 2023
Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trialsAvani Athauda, Matthew Nankivell, Rupert Langer, et al.
British Journal of Cancer|December 20, 2023
Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trialBianca Grosser, Jake Emmerson, Nic G Reitsam, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesotheliomaNeelam Kumar, Doraid Alrifai, Krishna K Kolluri, et al.
The Lancet. Respiratory Medicine|February 10, 2015
Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trialNeal Navani, Matthew Nankivell, David R Lawrence, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|June 28, 2020
Histological intratumoral heterogeneity in pretreatment esophageal cancer biopsies predicts survival benefit from neoadjuvant chemotherapy: results from the UK MRC OE02 trialNaser Davarzani, Lindsay C Hewitt, Matthew D Hale, et al.
Histopathology|February 22, 2018
Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trialNasser Davarzani, Gordon G A Hutchins, Nicholas P West, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2017
Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) ChemotherapyElizabeth Smyth, Shenli Zhang, David Cunningham, et al.
BMC Pharmacology & Toxicology|January 24, 2026
Drug re-purposing to improve outcomes in the management of prostate cancer - aims, outcome measures and design of current phase III trialsDuncan C Gilbert, Ruth E Langley, Dami Ayadi, et al.
Lancet (London, England)|June 5, 2007
Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic reviewDavid Gilligan, Marianne Nicolson, Ian Smith, et al.
JAMA Oncology|February 28, 2017
Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) TrialElizabeth C Smyth, Andrew Wotherspoon, Clare Peckitt, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|March 25, 2023
Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trialsAvani Athauda, Matthew Nankivell, Rupert Langer, et al.
British Journal of Cancer|December 20, 2023
Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trialBianca Grosser, Jake Emmerson, Nic G Reitsam, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesotheliomaNeelam Kumar, Doraid Alrifai, Krishna K Kolluri, et al.
The Lancet. Respiratory Medicine|February 10, 2015
Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trialNeal Navani, Matthew Nankivell, David R Lawrence, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|June 28, 2020
Histological intratumoral heterogeneity in pretreatment esophageal cancer biopsies predicts survival benefit from neoadjuvant chemotherapy: results from the UK MRC OE02 trialNaser Davarzani, Lindsay C Hewitt, Matthew D Hale, et al.
Histopathology|February 22, 2018
Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trialNasser Davarzani, Gordon G A Hutchins, Nicholas P West, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2017
Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) ChemotherapyElizabeth Smyth, Shenli Zhang, David Cunningham, et al.
BMC Pharmacology & Toxicology|January 24, 2026
Drug re-purposing to improve outcomes in the management of prostate cancer - aims, outcome measures and design of current phase III trialsDuncan C Gilbert, Ruth E Langley, Dami Ayadi, et al.
Lancet (London, England)|June 5, 2007
Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic reviewDavid Gilligan, Marianne Nicolson, Ian Smith, et al.
JAMA Oncology|February 28, 2017
Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) TrialElizabeth C Smyth, Andrew Wotherspoon, Clare Peckitt, et al.
Pageof 5